Emerald Clinics Ltd (ASX:EMD) has been as much as 40% higher this morning on news that it intends to change its name to Emyria Limited as part of a rebranding consistent with its global ambitions and expanded offerings.
A notice of a general meeting to approve the name change will be sent to shareholders shortly with the ASX code of EMD to remain unchanged.
Emerald Clinics CEO Dr Michael Winlo said: “Emerald Clinics has developed a trusted brand within Australia that resonates with clinicians and patients, but as our business has evolved and as we increase engagements overseas, it has become clear that a rebrand was the best way forward to help communicate the breadth of what we do and our global aspirations.
“Emyria speaks to our mission to use a myriad of data to provide individualised care beyond the physical confines of a clinic.”
Shares have been up to 40% higher to 8.5 cents this morning and are currently trading at 7.6 cents.
“Moving to international markets”
The planned name change follows the announcement on August 10, 2020, of a data collaboration with a UK partner, demonstrating the global desirability of the companys Real-World Evidence asset and the unique care model that supports it.
Dr Winlo said: “The recently announced data deal is the first step towards bringing our evidence-generating care model to international markets and we expect to build off that quickly in several geographies and across different health monitoring applications, where our Real-World Evidence asset can be utilised.
“In this next normal, leveraging remote data capture and real-time health monitoring to improve care and deliver insights that Read More – Source